Huang, Phoebe A.
Beedie, Shaunna L.
Chau, Cindy H.
Venzon, David J. http://orcid.org/0000-0002-8990-158X
Gere, Sheryl
Kazandjian, Dickran
Korde, Neha http://orcid.org/0000-0002-5538-4318
Mailankody, Sham
Landgren, Ola
Figg, William D.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA 008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 10 April 2019
Accepted: 3 September 2019
First Online: 16 October 2019
Competing interests
: O.L. receives grant support from NIH, FDA, MMRF, IMF, LLS, Perelman Family Foundation, Rising Tides Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, and Karyopharm. He is a member of the following Honoraria/Advisory Boards: Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, and Pfizer. He also serves as Chairman for “Medscape Myeloma” (2014-ongoing) and is a member of the Independent Data Monitoring Committee (IDMC) for Takeda, Merck, Janssen, and Theradex. All other authors declare no potential conflict of interest.